Want to see PBSV full AI Analyst Report?
Top Page
Pharma Bio Services
(OTC:PBSV)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.43
▼(-21.30% Downside)
Action:Reiterated
Date:09/16/26
The score is held down primarily by weak financial performance—recent losses and sustained negative operating/free cash flow—despite a notably strong, low-debt balance sheet. Technicals add additional pressure with the stock trading below key moving averages and negative MACD. Valuation is also constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Extremely Low Leverage
Extremely low debt and a sizable equity base reduce solvency pressure and preserve financial flexibility. This gives the company more capacity to absorb operating volatility and fund a recovery without the immediate burden of heavy interest obligations or refinancing needs.
Negative Factors
Sustained Loss-Making Performance
The shift from profitability in 2022–2023 to losses in 2024–2025 and the TTM period shows that revenue growth is not currently translating into earnings. Persistent negative margins weaken internal funding capacity and raise questions about the sustainability of the operating model.
Read all positive and negative factors
Positive Factors
Negative Factors
Extremely Low Leverage
Extremely low debt and a sizable equity base reduce solvency pressure and preserve financial flexibility. This gives the company more capacity to absorb operating volatility and fund a recovery without the immediate burden of heavy interest obligations or refinancing needs.
Read all positive factors
Pharma Bio Services (PBSV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.08M
Dividend Yield15.31%
Average Volume (3M)1.64K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth3.25%
EPS GrowthN/A
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)-0.36
Shares Outstanding22,901,691
10 Day Avg. Volume3,203
30 Day Avg. Volume1,641
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)1.04
Price to Sales (P/S)1.38
P/FCF Ratio-55.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)$11.70M
Pharma Bio Services Business Overview & Revenue Model
Company Description
Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the...
How the Company Makes Money
null...
Pharma Bio Services Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
82
Very Positive
Cash Flow
29
Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.48M | 9.00M | 9.51M | 16.98M | 19.40M | 20.12M |
| Gross Profit | 3.07M | 2.91M | 2.52M | 5.07M | 4.88M | 5.36M |
| EBITDA | -24.26K | 134.81K | -1.11M | 1.31M | 1.23M | -3.78M |
| Net Income | -13.95M | -100.46K | -777.62K | 1.31M | 1.01M | -2.09M |
Balance Sheet | ||||||
| Total Assets | 11.44B | 13.65M | 16.29M | 19.90M | 20.65M | 23.92M |
| Cash, Cash Equivalents and Short-Term Investments | 8.58M | 10.85M | 12.75M | 14.98M | 14.46M | 17.47M |
| Total Debt | 0.00 | 28.83K | 194.03K | 346.51K | 487.36K | 617.42K |
| Total Liabilities | 994.74M | 1.74M | 2.58M | 3.78M | 4.09M | 5.01M |
| Stockholders Equity | 10.44B | 11.91M | 13.72M | 16.13M | 16.56M | 18.91M |
Cash Flow | ||||||
| Free Cash Flow | -304.53M | -221.53K | -726.44K | 1.88M | 573.19K | 794.00K |
| Operating Cash Flow | -304.53M | -214.89K | -566.70K | 1.89M | 592.46K | 804.84K |
| Investing Cash Flow | -2.21B | -1.47M | -1.36M | -4.22M | -19.27K | 1.30M |
| Financing Cash Flow | -1.72B | -1.75M | -1.73M | -1.76M | -3.53M | -1.75M |
Pharma Bio Services Technical Analysis
Negative
0.54
Price Trends
0.50
Negative
0.53
Negative
0.51
Negative
Market Momentum
-0.02
Positive
43.13
Neutral
47.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBSV, the sentiment is Negative. The current price of 0.54 is above the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.50, and above the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.13 is Neutral, neither overbought nor oversold. The STOCH value of 47.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBSV.
Pharma Bio Services Risk Analysis
Pharma Bio Services disclosed 25 risk factors in its most recent earnings report. Pharma Bio Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pharma Bio Services Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $12.95M | -0.01 | -56.46% | ― | 116.40% | 99.31% | |
43 Neutral | $10.08M | -1.22 | -0.27% | 15.31% | 3.25% | ― | |
43 Neutral | $9.14M | >-0.01 | -32.44% | ― | -28.30% | -86.74% | |
42 Neutral | $1.09M | -0.05 | -400.87% | ― | -9.31% | 89.43% |
* Healthcare Sector Average
PBSV
Pharma Bio Services
0.44
-0.07
-13.56%
ZCMD
Zhongchao
0.98
-839.74
-99.88%
HCTI
Healthcare Triangle
0.73
-152.27
-99.52%
VSEE
VSee Health
1.80
-49.39
-96.48%
ACON
Aclarion, Inc.
2.63
-5.40
-67.25%
BFRG
BullFrog AI Holdings, Inc.
0.76
-0.67
-46.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.